stockrowOruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) Free cash flow
Oruka Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$88.4M, compared with −$58.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$101.2M. Over the past ten years it has ranged from −$88.4M (fiscal 2025) to −$4.8M (fiscal 2019) — the current reading is the lowest in ten years. Oruka Therapeutics, Inc. ranks 452nd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$88.4M | — |
| FY2024 | −$58.0M | — |
| FY2023 | −$5.0M | — |
| FY2022 | −$10.9M | — |
| FY2021 | −$18.8M | — |
| FY2020 | −$7.7M | — |
| FY2019 | −$4.8M | — |
| FY2018 | −$8.2M | — |
| FY2017 | −$17.5M | — |
| FY2016 | −$15.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$33.1M | — |
| Mar 2026 | −$23.7M | — |
| Dec 2025 | −$22.7M | — |
| Sep 2025 | −$21.7M | — |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| AXSM Axsome Therapeutics, Inc. compare | −$82.6M |
| ORKA Oruka Therapeutics, Inc. | −$101.2M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. compare | −$179.3M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$567.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)